| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
| Targets |
DL-Mevalonolactone targets the mevalonate pathway, serving as a precursor for the synthesis of isoprenoids, sterols, and other important biomolecules. It is used to study the effect of statins on the prenylation of Ras and Rho GTPases, which are important for cell signaling and function. The compound's effects on mitochondrial membrane potential and calcium retention suggest that it may interact with mitochondrial function. Its role in the isoprenoid biosynthesis pathway makes it valuable for studying cholesterol synthesis and related metabolic processes.
|
|---|---|
| ln Vitro |
In vitro, DL-Mevalonolactone is used to study the isoprenoid biosynthesis pathways. It can reduce mitochondrial membrane potential, NAD(P)H content, and Ca²⁺ retention capacity in the brain, and also induces mitochondrial swelling. The compound's effects on mitochondrial function suggest that it may have significant biological activities beyond its role as a metabolic intermediate.
|
| ln Vivo |
In vivo, DL-Mevalonolactone is a precursor in the mevalonate pathway and is involved in the synthesis of isoprenoids and sterols. Its effects on mitochondrial function suggest that it may have physiological relevance beyond its role as a metabolic intermediate. However, the compound is primarily used as a research reagent to study the mevalonate pathway.
|
| Enzyme Assay |
In vitro non-cell enzyme assays for DL-Mevalonolactone are not standard, as the compound is primarily used as a substrate or precursor in metabolic studies. Its effects on mitochondrial function can be assessed using isolated mitochondria, where parameters such as membrane potential, NAD(P)H content, and calcium retention are measured.
|
| Cell Assay |
In vitro cell-based assays for DL-Mevalonolactone use various cell lines to study the mevalonate pathway and its effects on cell function. Cells are treated with the compound, and parameters such as cell viability, proliferation, and isoprenoid synthesis are assessed. The compound's effects on mitochondrial function can also be studied in cell-based models.
|
| Animal Protocol |
In vivo animal studies for DL-Mevalonolactone are primarily metabolic studies. The compound is administered to animals, and parameters such as cholesterol synthesis, isoprenoid levels, and mitochondrial function are assessed. The compound's effects on the mevalonate pathway and its downstream products are studied.
|
| ADME/Pharmacokinetics |
DL-Mevalonolactone has a molecular weight of 130.14 g/mol and a molecular formula of C₆H₁₀O₃. It is also known as (±)-Mevalonolactone, DL-Mevalonic acid lactone, and β-Hydroxy-β-methyl-δ-valerolactone. The compound appears as a white or colorless to yellow to orange powder, lump, or clear liquid with a melting point of 28°C. It has a purity of ≥98%. Detailed pharmacokinetic parameters have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
The toxicity profile of DL-Mevalonolactone has not been comprehensively evaluated in published studies. As a metabolic intermediate, it is generally considered to have low toxicity. The compound's effects on mitochondrial function suggest that it may have significant biological effects at high concentrations. The compound is classified as a research reagent and is not intended for human therapeutic use.
|
| References |
|
| Additional Infomation |
4-Hydroxy-4-methyloxacyclohexanone-2-one belongs to the 2-pyranone class of compounds. It is a compound in which tetrahydro-2H-pyran-2-one is substituted with a methyl group and a hydroxyl group at the 4-position. It is a plant metabolite. It is both a 2-pyranone compound and a tertiary alcohol. It has been reported that 4-hydroxy-4-methyltetrahydro-2H-pyran-2-one exists in Phaeosphaeria herpotrichoides, soybean (Glycine max), and common bean (Phaseolus vulgaris), and relevant data are available.
DL-Mevalonolactone is a lactone form of mevalonic acid. It is also known as (±)-Mevalonolactone, DL-Mevalonic acid lactone, and β-Hydroxy-β-methyl-δ-valerolactone. The compound is used to study the effect of statins on the prenylation of Ras and Rho GTPases and to analyze the isoprenoid biosynthesis pathways. DL-Mevalonolactone can reduce mitochondrial membrane potential, NAD(P)H content, and Ca²⁺ retention capacity in the brain, and also induces mitochondrial swelling. Not approved for clinical use; intended for research purposes only. |
| Molecular Formula |
C6H10O3
|
|---|---|
| Molecular Weight |
130.1418
|
| Exact Mass |
130.063
|
| CAS # |
674-26-0
|
| PubChem CID |
10428
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.189 g/cm3
|
| Boiling Point |
145-150 °C5 mm Hg(lit.)
|
| Melting Point |
28 °C(lit.)
|
| Flash Point |
>230 °F
|
| Index of Refraction |
n20/D 1.473(lit.)
|
| LogP |
0.074
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
132
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(C([H])([H])C(C([H])([H])[H])(C([H])([H])C1([H])[H])O[H])=O
|
| InChi Key |
JYVXNLLUYHCIIH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H10O3/c1-6(8)2-3-9-5(7)4-6/h8H,2-4H2,1H3
|
| Chemical Name |
4-hydroxy-4-methyloxan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~768.40 mM)
H2O : ~50 mg/mL (~384.20 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (15.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (15.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (15.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 110 mg/mL (845.24 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.6840 mL | 38.4202 mL | 76.8403 mL | |
| 5 mM | 1.5368 mL | 7.6840 mL | 15.3681 mL | |
| 10 mM | 0.7684 mL | 3.8420 mL | 7.6840 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
